Newsroom | 49876 results

RESEARCH TRIANGLE PARK, N.C. & NOTTINGHAM, England--(BUSINESS WIRE)--Worldwide Clinical Trials (“Worldwide” or the “Company”), a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization with highly complementary strengths in oncology, biometrics, and FSP capabilities, substantially enhancing Worl...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are sc...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazyva® (obinutuzumab). Results show that significantly more people achieved complete remission at two years (104 weeks) with Gazyva versus tacrolimus. Safety was in line with the well-charac...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 10, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 7,500 shares of the Company’s common stock and restricted stock units (RSUs)...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.  MEDIPOST’s investigational therapy is an umbilical cord...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the...

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines: Symbicort (budesonide/form...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. “We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retr...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026....

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support informed diagnostic and disease management decisions. According to a study by the American Cancer Society, only about 20% of eligible individu...